Neuronal effects of a nickel-piperazine/NO donor complex in rodents. (September 2015)

• Record Type: Journal Article
• Authors: Sanna, Maria Domenica; Monti, Martina; Casella, Luigi; Roggeri, Riccardo; Galeotti, Nicoletta; Morbidelli, Lucia
• Is Part Of: Pharmacological research. Volume 99(2015:Sep.)
• Page Start: 162
• Page End: 173
• Publication Date: 2015-09
• Subjects: Nitric oxide -- Central nervous system -- Locomotor behavior -- Anxiety -- Memory -- Depression; pbm beats per minutes -- HR heart rate -- iNOS inducible nitric oxide synthase -- i.p. intraperitoneal -- NO nitric oxide -- NORT novel object recognition test -- PKC protein kinase C -- TST tail suspension test; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2015.06.004
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: In the brain, NO is a very important molecule in the regulation of cerebral and extra cerebral cranial blood flow and arterial diameters. It is also importantly involved in many neuronal functions and innumerable roles of NO in many brain related disorders including epilepsy, schizophrenia, drug addiction, anxiety, major depression, have been postulated. The present study aimed to explore the neuronal role exerted by the metal-nonoate compound Ni(PipNONO)Cl, a novel NO donor whose vascular protective effects have been recently demonstrated. Ni(PipNONO)Cl showed antidepressant-like properties in the tail suspension test and antiamnesic activity in the passive avoidance test in the absence of any hypernociceptive response to a mechanical stimulus. These effects were related to the NO-releasing properties of the compound within the central nervous system as demonstrated by the increase of iNOS levels in the brain, spinal cord and dura mater. The modulation of neuronal functions appeared after acute and repeated treatment, showing the lack of any tolerance to neuronal effects. At the dose used (10 mg/kg i.p.), Ni(PipNONO)Cl did not induce any visible sign of toxicity and experiments were performed in the absence of locomotor impairments. In addition to the NO-related neuronal activities of Ni(PipNONO)Cl, the decomposition control compound Ni(Pip)Cl2 showed anxiogenic-like and procognitive effects. The present findings showed neuronal modulatory activity of Ni(PipNONO)Cl through a NO-mediated mechanism. The activities of the decomposition compound Ni(Pip)Cl2 attributed to Ni(PipNONO)Cl the capability to modulate additional neuronal functions independently from NO releasing properties extending and improving the therapeutic perspectives of the NO donor.